Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors

Toshiyuki Takeuchi, Shuta Tomida, Yasushi Yatabe, Takayuki Kosaka, Hirotaka Osada, Kiyoshi Yanagisawa, Tetsuya Mitsudomi, Takashi Takahashi

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

Purpose: This study was conducted to gain insight into the relationship between expression profiles and underlying genetic changes, which are known to be important for the pathogenesis of lung cancers. Methods: Expression profiles of 18,175 unique genes and three major targets for genetic changes, p53, epidermal growth factor receptor (EGFR), and K-ras, were investigated in 149 patients with non-small-cell lung cancer, including 90 patients with adenocarcinoma to determine their relationships with various clinicopathologic features and Gene Ontology (GO) terms. Results: This study successfully established a basis for expression profile-defined classification, which can classify adenocarcinomas into two major types, terminal respiratory unit (TRU) type and non-TRU type. Our GO term-based identifier of particular biologic processes, molecular functions, and cellular compartments clearly showed characteristic retention of normal peripheral lung features in TRU type, in sharp contrast to the significant association of non-TRU type with cell cycling and proliferation-related features. While significantly higher frequency of EGFR mutation was observed in TRU type, we found that the presence of EGFR mutations was a significant predictor of shorter postoperative survival for TRU type, independent of disease stage. We were also able to identify a set of genes in vivo with significant upregulation in the presence of EGFR mutations. Conclusion: This study has shed light on heterogeneity in lung cancers, especially in adenocarcinomas, by establishing a molecularly, genetically, and clinically relevant, expression profile-defined classification. Future studies using independent patient cohorts are warranted to confirm the prognostic significance of EGFR mutations in TRU-type adenocarcinoma.

Original languageEnglish
Pages (from-to)1679-1688
Number of pages10
JournalJournal of Clinical Oncology
Volume24
Issue number11
DOIs
Publication statusPublished - Apr 10 2006
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Adenocarcinoma
Mutation
Gene Ontology
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Genes
Up-Regulation
Cell Proliferation
Adenocarcinoma of lung
Lung
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. / Takeuchi, Toshiyuki; Tomida, Shuta; Yatabe, Yasushi; Kosaka, Takayuki; Osada, Hirotaka; Yanagisawa, Kiyoshi; Mitsudomi, Tetsuya; Takahashi, Takashi.

In: Journal of Clinical Oncology, Vol. 24, No. 11, 10.04.2006, p. 1679-1688.

Research output: Contribution to journalArticle

Takeuchi, Toshiyuki ; Tomida, Shuta ; Yatabe, Yasushi ; Kosaka, Takayuki ; Osada, Hirotaka ; Yanagisawa, Kiyoshi ; Mitsudomi, Tetsuya ; Takahashi, Takashi. / Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 11. pp. 1679-1688.
@article{d10349bee8124744b0410bd3cef44411,
title = "Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors",
abstract = "Purpose: This study was conducted to gain insight into the relationship between expression profiles and underlying genetic changes, which are known to be important for the pathogenesis of lung cancers. Methods: Expression profiles of 18,175 unique genes and three major targets for genetic changes, p53, epidermal growth factor receptor (EGFR), and K-ras, were investigated in 149 patients with non-small-cell lung cancer, including 90 patients with adenocarcinoma to determine their relationships with various clinicopathologic features and Gene Ontology (GO) terms. Results: This study successfully established a basis for expression profile-defined classification, which can classify adenocarcinomas into two major types, terminal respiratory unit (TRU) type and non-TRU type. Our GO term-based identifier of particular biologic processes, molecular functions, and cellular compartments clearly showed characteristic retention of normal peripheral lung features in TRU type, in sharp contrast to the significant association of non-TRU type with cell cycling and proliferation-related features. While significantly higher frequency of EGFR mutation was observed in TRU type, we found that the presence of EGFR mutations was a significant predictor of shorter postoperative survival for TRU type, independent of disease stage. We were also able to identify a set of genes in vivo with significant upregulation in the presence of EGFR mutations. Conclusion: This study has shed light on heterogeneity in lung cancers, especially in adenocarcinomas, by establishing a molecularly, genetically, and clinically relevant, expression profile-defined classification. Future studies using independent patient cohorts are warranted to confirm the prognostic significance of EGFR mutations in TRU-type adenocarcinoma.",
author = "Toshiyuki Takeuchi and Shuta Tomida and Yasushi Yatabe and Takayuki Kosaka and Hirotaka Osada and Kiyoshi Yanagisawa and Tetsuya Mitsudomi and Takashi Takahashi",
year = "2006",
month = "4",
day = "10",
doi = "10.1200/JCO.2005.03.8224",
language = "English",
volume = "24",
pages = "1679--1688",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors

AU - Takeuchi, Toshiyuki

AU - Tomida, Shuta

AU - Yatabe, Yasushi

AU - Kosaka, Takayuki

AU - Osada, Hirotaka

AU - Yanagisawa, Kiyoshi

AU - Mitsudomi, Tetsuya

AU - Takahashi, Takashi

PY - 2006/4/10

Y1 - 2006/4/10

N2 - Purpose: This study was conducted to gain insight into the relationship between expression profiles and underlying genetic changes, which are known to be important for the pathogenesis of lung cancers. Methods: Expression profiles of 18,175 unique genes and three major targets for genetic changes, p53, epidermal growth factor receptor (EGFR), and K-ras, were investigated in 149 patients with non-small-cell lung cancer, including 90 patients with adenocarcinoma to determine their relationships with various clinicopathologic features and Gene Ontology (GO) terms. Results: This study successfully established a basis for expression profile-defined classification, which can classify adenocarcinomas into two major types, terminal respiratory unit (TRU) type and non-TRU type. Our GO term-based identifier of particular biologic processes, molecular functions, and cellular compartments clearly showed characteristic retention of normal peripheral lung features in TRU type, in sharp contrast to the significant association of non-TRU type with cell cycling and proliferation-related features. While significantly higher frequency of EGFR mutation was observed in TRU type, we found that the presence of EGFR mutations was a significant predictor of shorter postoperative survival for TRU type, independent of disease stage. We were also able to identify a set of genes in vivo with significant upregulation in the presence of EGFR mutations. Conclusion: This study has shed light on heterogeneity in lung cancers, especially in adenocarcinomas, by establishing a molecularly, genetically, and clinically relevant, expression profile-defined classification. Future studies using independent patient cohorts are warranted to confirm the prognostic significance of EGFR mutations in TRU-type adenocarcinoma.

AB - Purpose: This study was conducted to gain insight into the relationship between expression profiles and underlying genetic changes, which are known to be important for the pathogenesis of lung cancers. Methods: Expression profiles of 18,175 unique genes and three major targets for genetic changes, p53, epidermal growth factor receptor (EGFR), and K-ras, were investigated in 149 patients with non-small-cell lung cancer, including 90 patients with adenocarcinoma to determine their relationships with various clinicopathologic features and Gene Ontology (GO) terms. Results: This study successfully established a basis for expression profile-defined classification, which can classify adenocarcinomas into two major types, terminal respiratory unit (TRU) type and non-TRU type. Our GO term-based identifier of particular biologic processes, molecular functions, and cellular compartments clearly showed characteristic retention of normal peripheral lung features in TRU type, in sharp contrast to the significant association of non-TRU type with cell cycling and proliferation-related features. While significantly higher frequency of EGFR mutation was observed in TRU type, we found that the presence of EGFR mutations was a significant predictor of shorter postoperative survival for TRU type, independent of disease stage. We were also able to identify a set of genes in vivo with significant upregulation in the presence of EGFR mutations. Conclusion: This study has shed light on heterogeneity in lung cancers, especially in adenocarcinomas, by establishing a molecularly, genetically, and clinically relevant, expression profile-defined classification. Future studies using independent patient cohorts are warranted to confirm the prognostic significance of EGFR mutations in TRU-type adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=33645804773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645804773&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.8224

DO - 10.1200/JCO.2005.03.8224

M3 - Article

C2 - 16549822

AN - SCOPUS:33645804773

VL - 24

SP - 1679

EP - 1688

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -